loading page

Multiple Lineage Switches in KMT2A Rearranged Infant Leukemia, Responsive to Combination Therapy with CPX-351 and Inotuzumab
  • +1
  • Justin Sperlazza,
  • Jonathan Galeotti,
  • George Hucks,
  • Thomas Alexander
Justin Sperlazza
The University of North Carolina at Chapel Hill
Author Profile
Jonathan Galeotti
The University of North Carolina at Chapel Hill
Author Profile
George Hucks
The University of North Carolina at Chapel Hill
Author Profile
Thomas Alexander
The University of North Carolina at Chapel Hill

Corresponding Author:[email protected]

Author Profile

Abstract

Rearrangements of the KMT2A gene are characteristic of infantile acute lymphoblastic leukemia (ALL) and are associated with increased lineage plasticity and resistance to therapy. Here, we describe the case of a 9-month-old infant with infantile ALL who experienced multiple immunophenotypic switches in her leukemia throughout therapy and ultimately achieved remission with the combination of CPX-351 and Inotuzumab. This case highlights the unique clinical challenges infantile ALL poses on monitoring therapeutic response with current methods of measuring minimal residual disease as well as the challenges in treating infantile B-ALL.
07 Aug 2023Submission Checks Completed
07 Aug 2023Assigned to Editor
07 Aug 2023Submitted to Pediatric Blood & Cancer
07 Aug 2023Review(s) Completed, Editorial Evaluation Pending
09 Aug 2023Editorial Decision: Revise Minor
12 Aug 2023Assigned to Editor
12 Aug 2023Submission Checks Completed
12 Aug 20231st Revision Received
12 Aug 2023Review(s) Completed, Editorial Evaluation Pending
13 Aug 2023Editorial Decision: Accept